Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine

Zhang, Ye; Lian, Jiangshan; Yu, Li; Wang, Jie-Pin; Huang, Chang–Xing; Bai, Xue–Fan; Wang, Jiuping

doi:10.1097/meg.0b013e32835ee516

Cited by 14 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Semiquantification of HBsAg, HBeAg, anti-HBs, anti-HBe, and anti-HBc antibodies was performed by electrochemiluminescence (Architect, Abbott Laboratories, and Abbott Park, IL, USA). Serum biochemical parameters were measured using an automatic analyzer (Hitachi 7170A, Hitachi Ltd, Tokyo, Japan) in Department of Clinical Laboratory of Tangdu Hospital (11). …”

Section: Methodsmentioning

confidence: 99%

Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection

et al. 2014

Self Cite

View full text Add to dashboard Cite

Background:Immune cells and molecules play a vital role in initiating, maintaining, regulating immunological homeostasis and inflammation in many pathological and physiological processes; however, the changes on expressions and functions of these cells and molecules in hepatitis B virus (HBV) infection have not been elucidated well.Objectives:The current study aimed to determine the expression pattern of different cytokines, chemokines, immune cells in HBV infection and their association with disease progression.Patients and Methods:Sixty-nine patients with chronic HBV infection were enrolled. Five immune cell subsets and 46 cytokines and chemokines were analyzed by flow cytometry and Luminex 200.Results:In comparison to healthy individuals and asymptomatic HBV carriers, expression of CXCL9, CXCL10, CXCL11, and IL-10 were elevated in patients with chronic active HBV and had positive correlation with ALT levels. In contrast, G-CSF, MCP-3, and IFN-γ levels were significantly decreased in patients with chronic active HBV infection in contrast to carriers and healthy individuals; however, these down regulations did not show any correlation with either virological findings or liver inflammation. Although the proportion of CD4+ CD25 high regulatory T cells (Tregs) was higher in patients with HBV infection than in healthy controls, no correlations were found between Tregs and other cytokines or chemokines.Conclusions:CXCR3-associated chemokines might contribute to liver inflammation in chronic hepatitis B, while MCP-3 and G-CSF were inhibited by HBV infection. Host immune response was suppressed as manifested by an increase in CD4+ CD25high Tregs and IL-10 as well as a decrease in IFN-γ. Exploiting the expression pattern of cytokine and chemokine may help to develop a better understanding of chronic HBV infection pathogenesis.

show abstract

Section: Methodsmentioning

confidence: 99%

Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, elucidating the mechanisms underlying the evolutionary basis of the drug resistance mutations is important for their prevention and control. Drug resistant mutations in RT have been extensively explored during antiviral therapy using NAs, including lamivudine (LMV)[32], adefovir (ADV)[33], entecavir (ETV)[34], telbivudine (LdT)[35] and tenofovir (TNF).…”

Section: Introductionmentioning

confidence: 99%

Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2

Kim¹,

Lee²,

Kim³

et al. 2017

WJG

View full text Add to dashboard Cite

AIMTo report naturally occurring mutations in the reverse transcriptase region (RT) of hepatitis B virus (HBV) polymerase from treatment naïve Korean chronic patients infected with genotype C2.METHODSHere, full-length HBV reverse transcriptase RT sequences were amplified and sequenced from 131 treatment naïve Korean patients chronically infected with hepatitis B genotype C2. The patients had two distinct clinical statuses: 59 patients with chronic hepatitis (CH) and 72 patients with hepatocellular carcinoma (HCC). The deduced amino acids (AAs) at 42 previously reported potential nucleos(t)ide analog resistance (NAr) mutation positions in the RT region were analyzed.RESULTSPotential NAr mutations involving 24 positions were found in 79 of the 131 patients (60.3%). Notably, AA substitutions at 2 positions (rt184 and rt204) involved in primary drug resistance and at 2 positions (rt80 and rt180) that functioned as secondary/compensatory mutations were detected in 10 patients (1 CH patient and 9 HCC patients) and 7 patients (1 CH and 6 HCC patients), respectively. The overall mutation frequencies in the HCC patients (3.17%, 96/3024 mutations) were significantly higher than the frequencies in the CH patients (2.09%, 52/2478 mutations) (P = 0.003). In addition, a total of 3 NAr positions, rt80, rt139 and rt204 were found to be significantly related to HCC from treatment naïve Korean patients.CONCLUSIONOur data showed that naturally occurring NAr mutations in South Korea might contribute to liver disease progression (particularly HCC generation) in chronic patients with genotype C2 infections.

show abstract

“…For the patients with resistance to LdT or ETV, adding ADV is recommended, but its antiviral efficacy and safety are not established [ 1 ]. A small sample survey showed that LdT + ADV combination therapy led to significant decreases in serum HBV DNA levels, normalization of ALT, and increased the rate of HBeAg seroconversion in patients with resistance to LdT [ 33 ].…”

Section: The Drug Resistance and Rescue Strategiesmentioning

confidence: 99%

Antiviral therapy for chronic hepatitis B in China

Zheng

Wang

Yang

2014

Med Microbiol Immunol

View full text Add to dashboard Cite

The vaccination program against hepatitis B virus (HBV) has greatly reduced the incidence of HBV infection. However, almost one-fourth of the HBV infected patients worldwide are still located in China. The healthcare burden from chronic HBV infection is a big challenge for the Chinese government and clinicians. Antiviral therapy plays a central role in controlling chronic HBV infection and preventing the disease progression. However, due to the specific economic and medical system issues, the first-line antiviral agents recommended by the AASLD and EASL have not been widely used for Chinese patients. In this review, we will discuss some key issues in the area of antiviral treatment for chronic hepatitis B in China.

show abstract

Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine

Cited by 14 publications

References 16 publications

Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection

Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection

Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2

Antiviral therapy for chronic hepatitis B in China

Contact Info

Product

Resources

About